Tweet
F1000Res
. 2021 Feb 3;10:64.
doi: 10.12688/f1000research.36396.3. eCollection 2021.
Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis
Shinta Oktya Wardhani 1 , Jonny Karunia Fajar 2 , Laksmi Wulandari 3 , Gatot Soegiarto 4 , Yeni Purnamasari 5 , Anisa Asmiragani 5 , Helnida Anggun Maliga 5 , Muhammad Ilmawan 5 , Gloriana Seran 6 , Dheka Sapti Iskandar 7 , Conchita Emiliana Ndapa 8 , Viviana Hamat 8 , Rafika Ajeng Wahyuni 5 , Linda Oktaviana Suci Cyntia 5 , Feronika Maryanti Maarang 9 , Yosef Andrian Beo 9 , Olivera Agnes Adar 8 , Iraky Mardya Rakhmadhan 5 , Emilia Tiara Shantikaratri 5 , Ayu Sekarani Damana Putri 5 , Rizqa Wahdini 5 , Endang Pati Broto 10 , Agnes Wanda Suwanto 11 , Fredo Tamara 2 , Aditya Indra Mahendra 2 , Eden Suryoiman Winoto 2 , Pratista Adi Krisna 2 , Harapan Harapan 12
Affiliations
- PMID: 34136130
- PMCID: PMC8182694
- DOI: 10.12688/f1000research.36396.3
Abstract
Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified Jadad scale and Newcastle-Ottawa scale for randomized controlled trial (RCT) and non - RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without CCP had a 1.32 times higher risk of mortality than those treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, could reduce the mortality rate among COVID-19 patients.
Keywords: COVID-19; convalescent plasma; mortality; outcomes; passive immunization.